A sham-controlled trial in this progressive, often debilitating disease showed patients treated with a radiofrequency device had longer 6-minute walk times and other benefits.
email article
An attempt to tie together the fragmented nature of heart failure (HF) care ultimately made no difference on clinical outcomes or care processes in the CONNECT-HF trial.
U.S. centers randomized to a quality improvement intervention had patients with a cumulative incidence of a first HF rehospitalization or death approaching 40% at 1 year, similar to usual care (adjusted HR 0.92, 95% CI 0.81-1.05), reported Adam DeVore MD, MHS, of Duke University School of Medicine in Durham, North Carolina.
Overall HF care quality too was indistinguishable between the intervention and control arms too. For example, intervention hospitals showed no meaningful improvements in getting more people on >50% target dosing of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and angiotensin receptor-neprilysin inhibition.